Citi Pharma (KAR:CPHL) Buyback Yield %: 0.00 (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KAR:CPHL Citi Pharma Ltd KAR:CPHL
15 GF Score
Price ₨72.50
! 1 Warning Sign
View Full Analysis

What is Citi Pharma Buyback Yield %?

Citi Pharma KAR:CPHL -0.64% 15 Buyback Yield % is 0.00 as of Jul. 25, 2026. GuruFocus rates KAR:CPHL with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 290 Drug Manufacturers companies, Citi Pharma ranks worse than 344827.24% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Citi Pharma's current buyback yield was 0.00%.

Citi Pharma Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Citi Pharma's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citi Pharma Buyback Yield % Chart

Citi Pharma Annual Data
Trend
Buyback Yield %

Citi Pharma Semi-Annual Data
Buyback Yield %

KAR:CPHL vs ZTS, UTHR, VTRS: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Citi Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Citi Pharma Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citi Pharma's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Citi Pharma's Buyback Yield % falls into.


KAR:CPHL
15GF Score
Citi Pharma Ltd KAR:CPHL
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citi Pharma Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Citi Pharma's Buyback Yield for the fiscal year that ended in . 20 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- ( + ) /
=N/A%

Citi Pharma's annualized Buyback Yield for the quarter that ended in . 20 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- ( + ) /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Citi Pharma (KAR:CPHL) has a Buyback Yield % of 0.00 as of Jul. 25, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Citi Pharma and its competitors. According to the industry distribution chart, Citi Pharma ranks #999999 out of 290 companies in the Drug Manufacturers industry.
Is Citi Pharma's Buyback Yield % too high?
Citi Pharma's current Buyback Yield % is 0.00. Based on the distribution chart, Citi Pharma ranks #999999 out of 290 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citi Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Citi Pharma's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Citi Pharma ranks #999999 out of 290 companies for Buyback Yield %. This places Citi Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Citi Pharma and its competitors. Citi Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citi Pharma stock overvalued right now?
Citi Pharma (KAR:CPHL) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Citi Pharma's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Citi Pharma (KAR:CPHL), the current Buyback Yield % is 0.00 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citi Pharma Business Description

Address 588 Q Block, M.A., Johar Town, Lahore, PB, PAK
Citi Pharma Ltd is engaged in the manufacturing and sale of pharmaceuticals, medical chemicals and botanical products. Its product portfolio includes API segment, Formulation segment, Cephalosporin formulation, and Nutraceuticals. The API segment includes Paracetamol, Penicillin/Amoxicillin, Levofloxacin, Cefixime/Cephalosporin, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, and Ibuprofen.
15GF Score

Get the complete analysis for KAR:CPHL

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₨72.50
Price